Are Wrinkle Treatments With AHAs, BHAs OTCs? FDA Issues Call For Data
This article was originally published in The Rose Sheet
Executive Summary
FDA is requesting information on the possible physiological effects of alpha hydroxy and beta hydroxy acids in wrinkle removers to help evaluate their regulatory status, according to a Dec. 31 Federal Register notice
You may also be interested in...
Is StriVectin Better Than Botox? Not Without NDA Approval, FDA Says
Klein-Becker's signature statement for StriVectin-SD anti-aging cream - "Better than Botox?" - constitutes a structure/function claim that would require the product to be regulated as a drug, the agency states in a 1warning letter recently posted on its Web site
Is StriVectin Better Than Botox? Not Without NDA Approval, FDA Says
Klein-Becker's signature statement for StriVectin-SD anti-aging cream - "Better than Botox?" - constitutes a structure/function claim that would require the product to be regulated as a drug, the agency states in a 1warning letter recently posted on its Web site
CFSAN Cosmetics Oversight Aided By NTP, CDER Collaboration
FDA's Center for Food Safety & Applied Nutrition is tapping the expertise of other agencies and centers within the Department of Health & Human Services to monitor emerging technologies related to cosmetics